BMEA

Biomea Fusion Inc · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website biomeafusion.com
Employees(FY) 103
ISIN US09077A1060

Performance

+29.59%

-21.51%

-50.34%

-81.06%

-43.56%

YTD

-79.08%

Profile

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

Advanced Technical Analysis

Technical Analysis of BMEA 2025-04-25

The stock indicators reflect a neutral sentiment overall, with the Moving Average Score at 50 indicating a balanced trend, while the Oscillators Score of 41 and Technical Score of 45 suggest a lack of strong momentum in either direction. This combination implies that the stock is currently in a consolidation phase, warranting cautious observatio...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of BMEA

Stock Rank

Recent News & Updates

2025-03-25 07:00
Biomea Fusion Announces Leadership Transition(Globenewswire)
2025-03-24 20:50
Biomea Fusion announces presentation of icovamenib preclinical, clinical data(Yahoo Finance)
2025-03-23 20:30
Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose(Globenewswire)
2025-03-02 19:00
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2025-02-26 19:00
Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes(Yahoo Finance)
2025-01-12 20:00
Biomea Fusion to Become a Diabetes & Obesity Medicines Company(Yahoo Finance)
2025-01-12 20:00
Biomea Fusion to Become a Diabetes and Obesity Medicines Company(Globenewswire)
2025-01-06 20:00
Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study(Globenewswire)
2025-01-05 20:04
Heres Why Biomea Fusion, Inc. (NASDAQ:BMEA) Is Among the Best Diabetes Stocks to Buy Under $10(Yahoo Finance)
2025-01-05 18:00
Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference(Globenewswire)
2024-12-16 21:41
Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday?(Yahoo Finance)
2024-12-16 19:10
Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes(Globenewswire)
2024-12-16 05:15
Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)(Globenewswire)
2024-12-12 04:02
Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)(Globenewswire)
2024-12-12 04:02
Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)(Yahoo Finance)
2024-12-09 03:01
Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia(Yahoo Finance)
2024-12-05 19:00
Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia(Globenewswire)
2024-12-02 03:05
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-11-17 19:00
Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)(Globenewswire)
2024-11-01 04:05
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-10-30 04:00
Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate(Globenewswire)
2024-10-29 04:46
Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights(Globenewswire)
2024-10-20 21:00
Biomea Fusion Announces Approval of icovamenib as International Nonproprietary Name for BMF-219(Globenewswire)
2024-10-15 04:05
Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 R(Globenewswire)
2024-10-09 20:57
Morning Movers: Arcadium Lithium surges after deal to be acquired(Yahoo Finance)
2024-10-06 21:00
Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)(Globenewswire)
2024-09-30 21:00
Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts(Globenewswire)
2024-09-27 00:20
FDA Removes Clinical Hold On Biomea Fusion's Early-Stage Trials For Potential Diabetes Candidate(Yahoo Finance)
2024-09-26 23:13
Biomeas stock bounces back as FDA lifts clinical hold on diabetes trials(Yahoo Finance)
2024-09-26 02:00
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials(Globenewswire)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout makes no recommendations regarding investment decisions based on this information. You are solely responsible for your investments. Please conduct your own research and consult qualified financial advisors before investing. Past performance does not guarantee future results.